Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024PRNewsWire • 05/30/24
Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract CancerPRNewsWire • 05/29/24
Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee VolunteerismPRNewsWire • 05/22/24
The 7 Top-Selling Cannabis Companies Ranked by Revenue: Which Weed Stocks to Buy?InvestorPlace • 05/08/24
Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care ConferencePRNewsWire • 05/01/24
Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial GuidancePRNewsWire • 05/01/24
Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024PRNewsWire • 04/24/24
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 04/24/24
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024PRNewsWire • 04/17/24
Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay OffSeeking Alpha • 04/15/24
Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual MeetingPRNewsWire • 04/10/24
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract CancerPRNewsWire • 04/02/24
Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024PRNewsWire • 03/12/24